Oncogenic signaling of MEK5-ERK5
DOI
10.1016/j.canlet.2017.01.034
Document Type
Journal Article
Publication Date
4-28-2017
Publication Title
Cancer Letters
Volume
392
First Page
51
Last Page
59
ISSN
3043835
Keywords
Cellular signaling, Kinase inhibitors, MEK5-ERK5, Mitogen-activated protein kinase, Targeted therapies
Abstract
Mitogen-activated protein kinases (MAPKs) regulate diverse cellular processes including proliferation, cell survival, differentiation, and apoptosis. While conventional MAPK constituents have well-defined roles in oncogenesis, the MEK5 pathway has only recently emerged in cancer research. In this review, we consider the MEK5 signaling cascade, focusing specifically on its involvement in drug resistance and regulation of aggressive cancer phenotypes. Moreover, we explore the role of MEK5/ERK5 in tumorigenesis and metastatic progression, discussing the discrepancies in preclinical studies and assessing its viability as a therapeutic target for anti-cancer agents.
Open Access
Green Accepted
Preprint
Repository Citation
Hoang, V., Yan, T., Cavanaugh, J., Flaherty, P., Beckman, B., & Burow, M. (2017). Oncogenic signaling of MEK5-ERK5. Cancer Letters, 392, 51-59. https://doi.org/10.1016/j.canlet.2017.01.034